Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Study protocol

Efficacy of paracetamol, diclofenac and advice for acute low back pain in general practice: design of a randomized controlled trial (PACE Plus)

Authors: M. Schreijenberg, P. A. J. Luijsterburg, Y. D. M. Van Trier, D. Rizopoulos, M. A. Koopmanschap, L. Voogt, C. G. Maher, B. W. Koes

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

Low back pain is common and associated with a considerable burden to patients and society. There is uncertainty regarding the relative benefit of paracetamol and diclofenac and regarding the additional effect of pain medication compared with advice only in patients with acute low back pain. This trial will assess the effectiveness of paracetamol, diclofenac and placebo for acute low back pain over a period of 4 weeks. Furthermore, this trial will assess the additional effectiveness of paracetamol, diclofenac and placebo compared with advice only for acute low back pain over a period of 4 weeks.

Methods

The PACE Plus trial is a multi-center, placebo-blinded, superiority randomized controlled trial in primary care, with a follow-up of 12 weeks. Patients with acute low back pain aged 18–60 years presenting in general practice will be included.
Patients are randomized into four groups: 1) Advice only (usual care conforming with the clinical guideline of the Dutch College of General Practitioners); 2) Advice and paracetamol; 3) Advice and diclofenac; 4) Advice and placebo. The primary outcome is low back pain intensity measured with a numerical rating scale (0–10). Secondary outcomes include compliance to treatment, disability, perceived recovery, costs, adverse reactions, satisfaction, sleep quality, co-interventions and adequacy of blinding.
Between group differences for low back pain intensity will be evaluated using a repeated measurements analysis with linear effects models. An economic evaluation will be performed using a cost-effectiveness analysis with low back pain intensity and a cost-utility analysis with quality of life. Explorative analyses will be performed to assess effect modification by predefined variables.
Ethical approval has been granted. Trial results will be released to an appropriate peer-viewed journal.

Discussion

This paper presents the design of the PACE Plus trial: a multi-center, placebo-blinded, superiority randomized controlled trial in primary care that will assess the effectiveness of advice only, paracetamol, diclofenac and placebo for acute low back pain.

Trial registration

Dutch Trial Registration NTR6089, registered September 14th, 2016. Protocol: Version 4, June 2016.
Literature
1.
go back to reference Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.CrossRef Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.CrossRef
2.
go back to reference Lambeek LC, van Tulder MW, Swinkels IC, Koppes LL, Anema JR, van Mechelen W. The trend in total cost of back pain in the Netherlands in the period 2002 to 2007. Spine. 2011;36(13):1050–8.CrossRefPubMed Lambeek LC, van Tulder MW, Swinkels IC, Koppes LL, Anema JR, van Mechelen W. The trend in total cost of back pain in the Netherlands in the period 2002 to 2007. Spine. 2011;36(13):1050–8.CrossRefPubMed
4.
go back to reference Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19(12):2075–94.CrossRefPubMedPubMedCentral Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19(12):2075–94.CrossRefPubMedPubMedCentral
5.
go back to reference Chavannes AW, Mens JMA, Koes BW, Lubbers WJ, Ostelo R, Spinnewijn WEM, Kolnaar BGM. NHG-guideline Non-specific low back pain (in Dutch). Huisarts Wet. 2005;48(3):113–23. Chavannes AW, Mens JMA, Koes BW, Lubbers WJ, Ostelo R, Spinnewijn WEM, Kolnaar BGM. NHG-guideline Non-specific low back pain (in Dutch). Huisarts Wet. 2005;48(3):113–23.
6.
go back to reference Williams CM, Maher CG, Latimer J, McLachlan AJ, Hancock MJ, Day RO, Lin CW. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384(9954):1586–96.CrossRefPubMed Williams CM, Maher CG, Latimer J, McLachlan AJ, Hancock MJ, Day RO, Lin CW. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384(9954):1586–96.CrossRefPubMed
7.
go back to reference Koes BW, Enthoven WT. Do patients with acute low-back pain need paracetamol? Lancet. 2014;384(9954):1556–7.CrossRefPubMed Koes BW, Enthoven WT. Do patients with acute low-back pain need paracetamol? Lancet. 2014;384(9954):1556–7.CrossRefPubMed
8.
go back to reference Roelofs P, Deyo R, Koes B, Scholten R, van Tulder M. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;1:CD000396. Roelofs P, Deyo R, Koes B, Scholten R, van Tulder M. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;1:CD000396.
9.
go back to reference Foundation for Pharmaceutical Statistics. Facts and Figures 2016 (in Dutch). Hague; 2016. Foundation for Pharmaceutical Statistics. Facts and Figures 2016 (in Dutch). Hague; 2016.
10.
go back to reference Van der Linden M, Westert G, De Bakker D, Schellevis F. Second national study of diseases and therapies in primary care. Complaints and disorders in the population and in general practice (in Dutch). Utrecht/Bilthoven: NIVEL/RIVM; 2004. Van der Linden M, Westert G, De Bakker D, Schellevis F. Second national study of diseases and therapies in primary care. Complaints and disorders in the population and in general practice (in Dutch). Utrecht/Bilthoven: NIVEL/RIVM; 2004.
11.
go back to reference Svarstad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–24.CrossRefPubMed Svarstad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–24.CrossRefPubMed
12.
go back to reference Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1983;8(2):141–4.CrossRefPubMed Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1983;8(2):141–4.CrossRefPubMed
13.
go back to reference Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff (in Dutch). Ned Tijdschr Geneesk. 2005;149(28):1574–8. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff (in Dutch). Ned Tijdschr Geneesk. 2005;149(28):1574–8.
14.
go back to reference Bouwmans CA, Hakkaart-van Roijen L, Koopmanschap MA, Krol M, Severens JL, Brouwer WBF. Manual of the iMTA Medical Consumption Questionnaire (iMCQ) (in Dutch). Rotterdam: iMTA, Erasmus University Rotterdam; 2013. Bouwmans CA, Hakkaart-van Roijen L, Koopmanschap MA, Krol M, Severens JL, Brouwer WBF. Manual of the iMTA Medical Consumption Questionnaire (iMCQ) (in Dutch). Rotterdam: iMTA, Erasmus University Rotterdam; 2013.
15.
go back to reference Bouwmans CA, Hakkaart-van Roijen L, Koopmanschap MA, Krol M, Severens JL, Brouwer WBF. Manual of the iMTA Productivity Cost Questionnaire (iPCQ). Rotterdam: iMTA, Erasmus University Rotterdam; 2013. Bouwmans CA, Hakkaart-van Roijen L, Koopmanschap MA, Krol M, Severens JL, Brouwer WBF. Manual of the iMTA Productivity Cost Questionnaire (iPCQ). Rotterdam: iMTA, Erasmus University Rotterdam; 2013.
16.
go back to reference Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefPubMed Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefPubMed
17.
go back to reference Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–20. 22.CrossRefPubMed Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–20. 22.CrossRefPubMed
18.
go back to reference Hill JC, Dunn KM, Main CJ, Hay EM. Subgrouping low back pain: a comparison of the STarT back tool with the Orebro musculoskeletal pain screening questionnaire. Eur J Pain. 2010;14(1):83–9.CrossRefPubMedPubMedCentral Hill JC, Dunn KM, Main CJ, Hay EM. Subgrouping low back pain: a comparison of the STarT back tool with the Orebro musculoskeletal pain screening questionnaire. Eur J Pain. 2010;14(1):83–9.CrossRefPubMedPubMedCentral
19.
go back to reference Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.CrossRefPubMedPubMedCentral Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.CrossRefPubMedPubMedCentral
20.
go back to reference Dutch National Health Care Institute. Guideline for economic evaluations in healthcare (in Dutch). The Hague; 2016. Dutch National Health Care Institute. Guideline for economic evaluations in healthcare (in Dutch). The Hague; 2016.
21.
go back to reference Hakkaart-van Roijen L, Van der Linden N, Bouwmans CA, Kanters T, Swan Tan S. Budget Impact Analysis: Methodology for cost studies and reference prices for economic evaluation in health care (in Dutch). The Hague: Dutch National Health Care Institute; 2016. Hakkaart-van Roijen L, Van der Linden N, Bouwmans CA, Kanters T, Swan Tan S. Budget Impact Analysis: Methodology for cost studies and reference prices for economic evaluation in health care (in Dutch). The Hague: Dutch National Health Care Institute; 2016.
Metadata
Title
Efficacy of paracetamol, diclofenac and advice for acute low back pain in general practice: design of a randomized controlled trial (PACE Plus)
Authors
M. Schreijenberg
P. A. J. Luijsterburg
Y. D. M. Van Trier
D. Rizopoulos
M. A. Koopmanschap
L. Voogt
C. G. Maher
B. W. Koes
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1432-5

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue